Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment.

[1]  R. Steinman,et al.  Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. , 2006, Blood.

[2]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[3]  Giuseppe Leone,et al.  Tolerogenic dendritic cells: cytokine modulation comes of age. , 2006, Blood.

[4]  Hua Tang,et al.  Endothelial stroma programs hematopoietic stem cells to differentiate into regulatory dendritic cells through IL-10. , 2006, Blood.

[5]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[6]  S. Ferrari,et al.  Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. , 2006, Blood.

[7]  S. Tucker,et al.  Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. , 2006, Journal of the American Academy of Dermatology.

[8]  T. Giese,et al.  In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. , 2006, Blood.

[9]  R. Houot,et al.  Human CD4+CD25high Regulatory T Cells Modulate Myeloid but Not Plasmacytoid Dendritic Cells Activation , 2006, The Journal of Immunology.

[10]  J. Ott,et al.  Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. , 2006, The Journal of investigative dermatology.

[11]  M. Tagawa,et al.  Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. , 2006, Cellular & molecular immunology.

[12]  S. Ansell,et al.  Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. , 2005, Blood.

[13]  R. Dummer,et al.  Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. , 2005, Journal of the National Cancer Institute.

[14]  M. Dorf,et al.  Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor , 2005, The Journal of experimental medicine.

[15]  T. Bieber,et al.  Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3‐expressing lymphocytes into the skin following treatment with the TLR7‐agonist imiquimod , 2005, Journal of cutaneous pathology.

[16]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[17]  S. Rutella,et al.  Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. , 2004, Immunology letters.

[18]  L. Golitz,et al.  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. , 2004, Journal of the American Academy of Dermatology.

[19]  H. Gollnick,et al.  Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. , 2003, Journal of the National Cancer Institute.

[20]  Wing Hung Wong,et al.  Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. , 2003, Physiological genomics.

[21]  M. Stanley,et al.  Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential , 2002, Clinical and experimental dermatology.

[22]  M. Dhodapkar,et al.  The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. , 2002, Blood.

[23]  G. Trinchieri,et al.  Interleukin-12 in anti-tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[24]  P. Allavena,et al.  Dendritic cells as a major source of macrophage‐derived chemokine/CCL22 in vitro and in vivo , 2001, European journal of immunology.

[25]  G. Halliday,et al.  Cytokine profiles in spontaneously regressing basal cell carcinomas , 2000, The British journal of dermatology.

[26]  F. Nestle,et al.  Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. , 1997, The American journal of pathology.

[27]  J. Kim,et al.  IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. , 1995, Journal of immunology.

[28]  D. Sredni,et al.  Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. , 1995, Journal of immunology.

[29]  L. Goldberg,et al.  Perturbation of Epidermal Langerhans Cells in Basal Cell Carcinomas , 1987, American journal of dermatopathology.

[30]  M. Tagawa,et al.  Expression of interleukin-21 and -23 in human esophageal tumors produced antitumor effects in nude mice. , 2004, Anticancer research.

[31]  R. Steinman,et al.  The interaction of immunodeficiency viruses with dendritic cells. , 2003, Current topics in microbiology and immunology.

[32]  D. Curiel,et al.  Selective transduction of murine myelomonocytic leukemia cells (WEHI-3B) with regular and RGD-adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.